Ticlopidin is a well-known antithrombocytic drug used in the prophylaxis of arteriosclerotic diseases. Ticlopidin is supposed to reduce ischemia reperfusion injury with its effects against platelet aggregation which play important roles in ischemia reperfusion injury by means of different mediators.

32 female Sprague-Dawley rats were randomised to four groups one being as control in the study design. Only anesthesia was performed to group 1 (n=8). The right hind limb ischemia was induced by tourniquets applied at the hip level group 2 (n=8). After 4 hours the samples were collected before tourniquets were removed. Group 3 (n=8) and group 4 (n=8) rats were randomised to 2 hours of reperfusion after 4 hours of ischemia. Ticlopidin (50 mg/day) were given five days before the experiment day twice daily to the animals in the group 4. Tissue malondialdehyde levels were recorded by thiobarbutiric acid method as a marker for lipid peroxidation.

According to the lung levels of malondialdehide, ticlopidin was found to be effective against lung reperfusion injury. Malondialdehide levels showed numerical reduction in the skeletal muscle and liver without reaching statistical significance. The persentage of viable cells were similar between the ticlopidin and control group and it showed significant decrease in ischemia and ischemia reperfusion groups. In this study it is approved that ticlopidin reduced the local and systemic effects of ischemia reperfusion injury of the skeletal muscle by hystopathologic and biochemical means.

Ticlopidin, used as a profilactic agent against chronic arteriosklerotic diseases can prevent ischemia reperfusion injury in acute ischemic occlusions.

Keywords :